Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-MS-1467 proof-of-concept trial in relapsing multiple sclerosis
2013-002916-28Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2013
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATX-MS-1467 in multiple sclerosis (MS), sponsored by Merck KGaA. Primary endpoint: Change in average number of T1 contrast-enhancing lesions. Started Oct 2013; status: completed.
02
Drugs
ATX-MS-1467
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-002916-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002916-28.